RLMD · Relmada Therapeutics, Inc. · Stock research

Current Thesis

The level this coverage had built the frame around went on 2026-08-21. The adjusted daily series closed the week at $4.63, beneath the $4.75 at which the March 2026 PIPE was struck — The condition published on 2026-08-15, a weekly close below $4.75, has therefore fired, and it fired quietly: no company release or fresh guidance surfaced in public news aggregation between the 2026-08-06 Q2 update and the 2026-08-21 close.

The narrative leg on offer is no longer the oncology-pivot re-rate that carried the name from the 2026-03-09 Phase 2 interim into the June Russell add. It is cash-covered optionality on a 2027 binary: an asset still pre-IND as of 2026-08-06, an FDA-agreed registrational design, $217.7M of cash and investments at 2026-06-30, and a first Phase 3 disclosure guided to 1H 2027 after 15–20 patients are evaluated. Between now and the year-end IND deadline there is no dated clinical event the company does not itself control.

Bullish and bearish views on Relmada Therapeutics, Inc.

The model's bull view on Relmada Therapeutics, Inc. (RLMD), in brief: The 2026-03-09 12-month Phase 2 interim: 95% complete response at any time, 76% CR at 12 months in high-risk NMIBC, 80% CR at 12 months in the BCG-unresponsive cohort, no progression to muscle-invasive disease, no radical cystectomies, no grade 3+ treatment-related adverse… The bear view: The only dated clinical event left in 2026 is a regulatory filing the company controls. Both cases follow in full.

Bull Case

• The 2026-03-09 12-month Phase 2 interim: 95% complete response at any time, 76% CR at 12 months in high-risk NMIBC, 80% CR at 12 months in the BCG-unresponsive cohort, no progression to muscle-invasive disease, no radical cystectomies, no grade 3+ treatment-related adverse events. The alternative in BCG-unresponsive disease is bladder removal.
• The 2026-08-06 release states design and primary endpoints for both registrational pathways were confirmed via written FDA feedback. The RESCUE primary endpoint is complete response rate at any time, crediting reinduction after three months rather than a fixed three-month assessment.
• Operational readiness runs ahead of the regulatory clock: roughly 80 sites engaged (60 primary, 20 backup), and on the 2026-08-06 call management said enrollment can technically begin 30 days after IND filing.
• $217.7M cash and investments at 2026-06-30 against Q2 operating cash use of $9.6M, guided through 2029 including completion of RESCUE. Q2 loss was $(0.11) per share versus a $(0.20) consensus estimate — the pre-Phase-3 burn is running under where the street modelled it.
• The sell-side did not follow the tape down after the guidance reset. Piper Sandler reiterated Buy with a $12 target on 2026-08-07, H.C. Wainwright Buy $12 on 2026-08-10, Mizuho Buy $19 on 2026-08-11. The S&P Global-polled consensus as of 2026-08-23 is Strong Buy, average $12.67 across six analysts, range $9.00–$19.00.
• Sepranolone remains an unpriced second asset, with IND guided by year-end 2026 and a Phase 2 proof-of-concept in Prader-Willi syndrome on clearance.

Bear Case

• The only dated clinical event left in 2026 is a regulatory filing the company controls. On 2026-08-06 the previously promised end-2026 three-month interim was replaced with 1H 2027 first Phase 3 data; in March the program had been guided to initiate mid-2026.
• The reason given for the slip was contract-manufacturing scheduling — an external dependency with no fix the company can announce. The same constraint gates the sepranolone pre-filled syringe, so both year-end 2026 INDs sit behind one bottleneck.
• The March book is now underwater. The $4.75 strike that had acted as a floor through the summer became a failed level on the 2026-08-21 weekly close, and the index-mechanical demand from the Russell 2000/3000 add effective 2026-06-26 is spent.
• An effective S-3 shelf remains on file. Runway guidance through 2029 removes the need to raise; it does not remove the option to.
• A $12.67 average target against a $4.63 close is a 2.7x gap on an unstarted trial. Pre-IND NPV models are not a floor and can be cut on timeline alone.
• The 2022-10-13 RELIANCE II failure of REL-1017 is the reason this management team gets no benefit of the doubt on a guidance reset.

Setup & Price Structure

The 2026-08-21 close of $4.63 sits 41.1% below the $7.86 52-week high; the shares are down 34.2% over three months, and RSI(14) reads 31.7 against 39.4 on 2026-08-14. That is a grind lower rather than a capitulation flush — a two-week continuation on no disclosure after the catalyst deletion, not a single gap.

The narrative is dead, applied to the narrative leg rather than to the company. The dating is specific — the re-rate ran from the 2026-03-09 interim through the 2026-06-26 index add, the forcing function was removed on 2026-08-06, and the price structure that held it broke on 2026-08-21 when the PIPE strike gave way. The $4.75 area now sits overhead. Below it the public record offers no post-March reference price, which is why the next gradeable break is set at a weekly close below $4.25.

Positioning and crowding observables, stated as observables: price is below rather than above a rising average, with RSI(14) at 31.7; three Buy targets were refreshed on 2026-08-07, 08-10 and 08-11 into a tape that fell over the following two weeks; the Russell-driven share of daily flow post-2026-06-26 is mechanical; an effective S-3 sits behind a stock trading under its last issue price; and there is no earnings date inside the next 30 days to force a repricing either way.

Catalyst Calendar (next 30 days)

• None company-confirmed between 2026-08-23 and 2026-09-22. No scheduled readout, filing deadline or investor event is on the public calendar in this window.
• ~2026-11-05 (est.) — Q3 2026 results and business update. First checkpoint on whether "by year-end 2026" for the NDV-01 IND survives, and the first read on burn as sites activate.
• 2026-12-31 — guided NDV-01 IND submission deadline. RESCUE cannot enroll before clearance.
• 2026-12-31 — guided sepranolone IND submission.
• ~2027-06-30 (est., 1H 2027 guided) — first Phase 3 RESCUE data after 15–20 patients evaluated.

What Would Change Our Mind

The structure that broke is reclaimable, and the reclaim is the cleanest constructive datapoint available before November: weekly closes back above $4.75 would put the March book whole again and re-establish the level the summer range was built on. An IND submission announced meaningfully ahead of 2026-12-31 would do more, because it converts the one 2026 event from a deadline into an evidence point and starts the 30-day clock to enrollment management described on 2026-08-06.

Continuation the other way is defined at a weekly close below $4.25, roughly 10% under the PIPE issue price and the point at which the post-March range has no remaining reference. Two non-price conditions would independently break what is left of the case: an IND submission not announced by 2026-12-31, which by management's own sequencing pushes first data past the guided 1H 2027; or a registered offering priced off the shelf, which would contradict the 2029 runway framing while the stock trades under $4.75. On the fundamental side, quarterly operating cash use stepping materially above the $9.6M Q2 rate before enrollment begins would make the runway guidance a moving number.

Correlation Notes

• No revenue, so the name carries no macro or customer correlation. What it does track is small-cap biotech risk appetite and the sector financing window — XBI-type beta, amplified by a sub-$500M market profile and a live shelf.
• Index-mechanical: added to the Russell 2000/3000 effective 2026-06-26, so a portion of daily volume follows index flows independent of the story.
• Read-across risk in NMIBC is one-directional here. Durable-CR datasets or approvals from J&J's TAR-200 or CG Oncology's cretostimogene set the bar NDV-01's 2027 data must clear, and ImmunityBio's Anktiva is already approved in the indication.
• Rate path matters through the discount rate on a 2027-plus cash-flow story with the entire value in terminal assumptions.